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Abstract Among mammals, camelids have a unique immuno-
logical system since they produce functional antibodies devoid of
light chains and CH1 domains. To bind antigens, whether they
are proteins or haptens, camelids use the single domain VH
from their heavy chain (VHH). We report here on such a llama
VHH domain (VHH-R9) which was raised against a hapten, the
RR6 red dye. This VHH possesses the shortest complementarity
determining region 3 (CDR3) among all the known VHH se-
quences and nevertheless binds RR6 e⁄ciently with a Kd value
of 83 nM. However, the crystal structure of VHH-R9 exhibits a
striking feature: its CDR3 and its last L-strand (L9) do not
follow the immunoglobulin VH domain fold, but instead extend
out of the VHH molecular boundary and associate with a sym-
metry-related molecule. The two monomers thus form a domain-
swapped dimer which establishes further contacts with symme-
try-related molecules and build a crystal-wide L-sheet structure.
The driving force of the dimer formation is probably the strain
induced by the short CDR3 together with the cleavage of the
¢rst seven residues.
/ 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The fundamental molecules dedicated to molecular recog-
nition in the humoral immune response are remarkably ho-
mogeneous throughout the vertebrate phylum [1]. Important
deviations of this conserved immunoglobulin organization
have been observed, however. In some immunoglobulin iso-
types of camelids from the old world (camels, dromedaries) or
from the new world (llamas, vicun‹a) the L chain is missing [2].
Furthermore, their H chain is devoid of the CH1 domain [3,4]
due to an unconventional splicing event during mRNA mat-
uration. The antigen binding fragment of the heavy-chain
antibodies therefore comprises a single domain, referred to
as VHH, that replaces a four-domain Fab fragment in the
immunoglobulin structure [5]. This VHH domain is obtained
after a DNA recombination between dedicated VHH germline
gene segments with D and J minigenes.
From a structural viewpoint, the three-dimensional struc-
tures of VHH unbound [6,7] or in complex with proteins such
as lysozyme, RNase, carbonic anhydrase, amylase [8^11] as
well as with two dye haptens [12,13], have been determined.
They all present a common architecture of the core, with the
characteristic mutations of camelid antibodies [14]. The com-
plementarity determining regions (CDRs) 1 and 2 present a
length within the average of classical antibodies, while CDR3
can be much longer than usually observed, presents a large
variety of conformations and is often stabilized by a disul¢de
bridge [14]. VHH-R9 was raised against the red dye hapten
RR6, for which it has good a⁄nity. VHH-R9 exhibits the
shortest CDR3 among camelid VHHs, to date. Its ¢rst L-
strand has been cleaved between residues 7 and 8 and lacks
the ¢rst seven residues. The VHH-R9 crystal structure reveals
that CDR3 and the last L-strand are swapped between sym-
metry-related molecules [15]. The resulting dimer forms a
crystal-wide L-sheet, a striking feature which involves mecha-
nisms comparable to those occurring during amyloid ¢ber
formation [15]. These ¢ndings could give clues on the phe-
nomena which could occur upon conformational changes of
VH domains resulting from the presence of short CDRs and
proteolytic cleavage.
2. Materials and methods
2.1. VHH preparation and characterization
A male llama (Lama glama) was immunized with a bovine serum
albumin (Sigma, A7888)-coupled RR6 azo dye (ICI, Procion Rubine
MX-B). Young adult male llamas were injected on days 0, 21 and 35
with 250 mg of the antigens mentioned above in Specol (ID-DLO,
Lelystad, The Netherlands). Blood samples of about 150 ml were
taken 7 days after the last immunization and peripheral blood cells
were obtained via Ficoll (Pharmacia) discontinuous gradient centrifu-
gation. From these cells, total RNA was isolated and synthesis of the
¢rst strand cDNA was performed (Amersham ¢rst strand cDNA kit).
DNA fragments encoding the VHH domain were ampli¢ed by poly-
merase chain reaction using speci¢c primers and were ligated into a
Saccharomyces cerevisiae expression plasmid. After transformation of
S. cerevisiae, the culture supernatants of single colonies where tested
via enzyme-linked immunosorbent assay for the production of RR6-
speci¢c VHH fragments. Several VHHs were obtained at very high
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yields (up to 100 mg/l of £ask culture). The R9 anti-RR6 fragment
was puri¢ed from crude yeast culture broth by a⁄nity chromatogra-
phy, using a protein A-Sepharose FF column (Pharmacia). More de-
tails on the VHH production procedure have been published else-
where [16].
Kinetic measurements were performed using an IAsys Biosensor
Instrument (Fisons) in phosphate-bu¡ered saline (10 mM Na2HPO4,
1 mM KH2PO4, 137 mM NaCl, pH 7.4) with 0.05% (v/v) Tween 20,
pH 7.4. RR6 was linked to aminosilane cuvettes. At least 10 dilutions
were injected into the cuvette. The resulting data were analyzed using
the FASTFIT software considering the association phase resulting in
association and dissociation constants.
Mass analysis of recombinant VHH-R9 was obtained with Voyag-
er-DE RP (PerSeptive Biosystems). Samples (0.7 Wl containing 15
pmol) were mixed with an equal volume of sinapinic acid matrix so-
lution and spotted on the target, then dried at room temperature for
10 min. The mass standard was apomyoglobin.
2.2. Crystallization, data collection and processing
Trials of crystallizations using Crystal Screen (Hampton Research)
were carried out at room temperature using the hanging drop method.
Crystals suitable for X-ray measurement were obtained at pH 7.5 with
the reservoir solution containing 26^28% (v/v) PEG 600 and 100 mM
HEPES bu¡er. An equi-amount of reservoir solution was added to
2 Wl of VHH-R9 (20 mg/ml), and the sample solution was equilibrated
over 1.0 ml reservoir solution. Crystals of dimensions 0.2U0.2U0.1
mm appeared in 4^5 weeks. VHH-R9 crystallized in the cubic space
group I4132 with unit cell dimensions of a= b= c=124.3 AS . They
contain one VHH-R9 molecule per asymmetric unit giving a Vm value
of 3.5 AS 3/Da [17]. It should be noticed that all attempts to crystallize
VHH-R9 in complex with its hapten failed.
Crystals were frozen at 100 K without cryoprotectant. One £ash-
frozen crystal was used for data collection on ID14EH2 (ESRF, Gre-
noble, France). Data were indexed and integrated with DENZO [18]
and scaled using SCALA [19]. The statistics of the data sets are shown
in Table 1.
2.3. Structure determination and re¢nement
The crystal structure was solved using molecular replacement
with the AMoRe program [20] in the resolution range 7.0^2.8 AS .
The anti-RR6 llama VHH-R2 (PDB: 1QD0) was used as the search
model [12]. A unique solution was found with a correlation coe⁄-
cient of 0.767 and an R factor of 33%, compared to the next highest
peak with values of 0.375 and 52.0%. Model building was performed
using the program Turbo-Frodo [21]. Crystallographic re¢nement
was carried out with the programs CNS [22] and REFMAC [23].
Some 9% of the measured re£ections were not included in the re¢ne-
ment procedure and served as a test set, yielding the R-free fac-
tor. Several rounds of re¢nement and model building yielded im-
proved maps. The ¢nal model was re¢ned to an R factor of 20.6%
and an R-free of 22.5% (Table 1). The stereochemistry of the ¢nal
model was analyzed by PROCHECK [24], 92.5% of the residues were
found to lie in the most favorable regions of the Ramachandran
plot and 4.8% in additionally allowed regions, and no residue was
found in forbidden regions. The coordinates have been deposited
with the Protein Data Bank at RCSB (http://www.rcsb.org/pdb/) as
entry 1SJV.
Table 1
Data collection, structure determination and re¢nement summary of
VHH-R9
Data collection R9
Total/unique number of re£ections 408 060/12 481
% of datas 1c (overall/last shell)a 98.6/98.6
Overall I/c(I) (last shell) 4.9/2.3
Resolution limits 30.0/1.94
R-merge (%) (overall/last shell)a 9.4/27.3
Re¢nement
Number of protein/solvent atoms 788/73
Number of re£ections 12 041
Resolution limits (AS ) 15.0^1.95
R/R-free value (%) 20.6/22.5
rmsd on bonds (AS ) and angles (‡) 0.013/1.7
Mean B factor (AS 2): main-chain atoms
main chain atoms 21.5
side chain atoms/solvent 24.0/29.0
aLast shell : 2.1^1.94 AS .
Fig. 1. Alignment of 10 sequences of camelid VHHs with known structures. From top to bottom: RR6-R9: llama VHH number 9 (raised
against red dye RR6, this work); RR6-R2: llama VHH number 2 (raised against red dye RR6, PDB entry 1QD0 [12]) ; RR1-52: llama VHH
number 52 (raised against red dye RR1, PDB entry 1I3V/1I38 [13]) ; hCG-H14: llama VHH number H14 (raised against hCG, PDB entry
1HCV [6]); cAb-LY3: camel VHH anti-lysozyme 3 (raised against lysozyme, PDB entry 1MEL [8]); cAb-RN05: camel VHH anti-RNase-5
(raised against RNAse, PDB entry 1B2Q [9]) ; cAb-CA05: camel VHH anti-carbonic anhydrase 5 (raised against carbonic anhydrase, PDB en-
try 1GGV [10]); AMYL-B07, -D09 and -D10: camel VHHs anti-amylase number B07, D09, D10 (raised against porcine amylase, PDB entries
1KXT, 1KXQ and 1KXV [11]). The CDR residues are colored red, green and blue for CDRs 1, 2 and 3, respectively. Cysteines are colored
yellow. Residues characteristic of camelid VHHs are colored pink. Numbering is that of Kabat et al. [37].
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3. Results
3.1. Characteristics of the anti-RR6 VHH-R9 sequence
The VHH-R9 fragment sequence is closely related to that of
the other VHH fragments from camel or llama of known 3D
structure (Fig. 1). It displays the four amino acid mutations
observed in all camelid VHHs as compared to classical VHs:
Val37Tyr (instead of Phe in most VHHs), Gly44Gln (instead
of Glu), Leu45Arg and Trp47Leu, the latter position being
sometimes substituted by Gly, Tyr, Phe and Ser in other
VHHs. VHH-R9 possesses two cysteines (Cys22 and Cys92)
forming the conserved disul¢de bridge present in all VH and
VHH domains. The CDR1 is nine residues long, a length
typical of most VHHs [14], and its CDR2 is seven residues
long, a value observed in many camelid VHH (Fig. 1). In
contrast, the CDR3 is only six residues long, a value largely
below the average size of CDR3 in camels or llamas (Fig. 1).
Very short CDR3s have been reported for classical antibodies,
though, such as that belonging to an immunoglobulin raised
against ampicillin [25]. However, VHH-R9 possesses the
shortest CDR3 observed in camels or llama antibodies, to
date.
3.2. Characterization of the VHH-R9
The a⁄nity of the VHH-R9 for RR6 has been measured on
an IAsys biosensor (Table 2). Its Kd value, measured on
freshly puri¢ed protein, was 83 nM, a value slightly higher
than but within the same order of magnitude as those ob-
served with other RR6 hapten binders (values between 22
and 58 nM, Table 2).
Matrix-assisted laser desorption/ionization mass spectrosco-
py performed on freshly puri¢ed protein yielded a single peak
at 12 610 Da, accounting for the intact VHH with pyroglut-
amine at position 1. The mass spectra performed on samples
of proteins remaining from crystallization experiments contain
several peaks. The main peak belongs to the intact native
VHH-R9 (MW=12 610). The three di¡erent peaks with lower
intensity at 12 028 Da, 11 899 Da and 11 813 Da were attrib-
uted to VHH-R9 missing the ¢rst ¢ve, six and seven amino
acids at the N-terminus, respectively. Peaks corresponding to
VHH-R9 dimers have also been observed, but at lower inten-
sity. The low intensity of the dimers in the mass spectrum
could be due to the acidic conditions of the experiment, since
sinapinic acid is the matrix used in these measurements.
3.3. The VHH-R9 structure and the domain swapped dimer
The complete VHH-R9 sequence consists of 114 amino
acids, numbered 1^113 (Fig. 1). Molecular replacement was
performed using as a starting model the core residues (CDRs
were excluded) of VHH-R2 (PDB entry 1QD0 [12]). As men-
tioned above, the ¢rst seven amino acids were not visible in
the electron density map, due to cleavage (see above). Residue
8 is a glycine forming a bulge between two stranded segments
and is very exposed to solvent in VHH structures, hence its
susceptibility to cleavage. The stretch of residues S25GNT28,
at the beginning of CDR1, could not be traced due to weak
Table 2
A⁄nity values of several llama VHHs for their antigen, the red dye
RR6
Llama VHH Kd (nM)
R2 22
R7 45
R8 20
R9 83
R10 58
Fig. 2. Structure of VHH-R9. A: Electron density map (2Fo3Fc) displaying the two extended L-strand stretches of residues Tyr93^Trp103 in
monomers A and B, forming the junction between the domain-swapped domains. The two stretches form an antiparallel L-structure well de-
¢ned in density. B: Ribbon representation of VHH-R9 monomer in rainbow coloring. The blue arrow between strands 2 and 3 indicates the
connectivity of CDR1, since a gap of four residues is present. C: The dimer reconstituted by associating the molecule in the asymmetric unit
(red) with the closest symmetry-related molecule (gray). The two functional units (FU) are labelled FU1 and FU2, and the free interface, FI.
The molecular surfaces are displayed in a semi-transparent fashion. View A was made with Turbo-Frodo [21], views B and C with PyMol [38].
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electron density. Contrary to the former case, this is due to
disorder since mass spectroscopy indicates the presence of
these residues. We encountered some di⁄culties when trying
to trace the CDR3. It became rapidly obvious that it was
impossible to model a loop, but that a long stretch of residues
was extending beyond the VHH molecular boundary, ¢rst in
the solvent, and then along a symmetry-related molecule (Fig.
2A,B). When crystal symmetry was applied, it became obvious
that VHH-R9 was displaying a domain-swapped structure
[15,26,27] : the last L-strand of each symmetry-related domain
was provided by its closest neighbor (Fig. 2C). The two sym-
metry-related molecules form a strongly bound anti-parallel
structure resembling a dumb-bell. Considered as a whole, the
incomplete VHH monomer and the last L-strand from the
other monomer reconstitute a classical VHH (not consider-
ing the CDR3), superimposable on other VHH structures.
This composite structure is called a functional unit (FU) in
the domain-swapping nomenclature [15], and the domain-
swapped elements between the two FUs are called free inter-
face (FI). It should be noticed, however, that in the case of
VHH-R9, the FU is no longer functional due to the destruc-
tion of the combining site. When superimposing the VHH-R9
FU with, e.g. VHH-52, all structural elements are well aligned
(rmsd of 1.04 AS on 94 amino acids kept in the alignment)
(Fig. 3A). The intricacy of the association in the crystal sug-
gests, as for other domain-swapped dimers, that it pre-exists
in solution. This is most likely true since the monomer surface
buried in the interaction is 1660 AS 2, on a total surface of 7680
AS 2. It accounts for 21% of the molecular surface, when values
above 8% have been shown to be relevant of biologically
relevant dimers [28]. Furthermore, the observation of a dimer
in harsh mass spectroscopy conditions reveals the strength of
the interaction. Such domain-swapped dimers have already
been observed by mass spectroscopy in similar conditions [27].
The driving force for the CDR3 opening and the projection
of the ninth strand outwards is probably twofold: ¢rst, the
short CDR3 should impose some strain on the VHH back-
bone; second, the depletion of residues 1^7 probably weakens
the interaction between the ninth strand and the rest of the
VHH. In VH or VHH domains, the N- and C-terminal clo-
sure involves interactions of strands 1a and 2, 1b and 9b, and
9b with 8 (Fig. 3B). This alternate pattern of interactions of
strand 1 ensures proper closure of the L-sandwich (Fig. 3B).
The lack of strand 1a weakens strand 9 position since: (i)
indirect interactions are normally established between strands
1a and 9b through water molecules; (ii) the lack of strand 1a
Fig. 3. Mechanism of domain swapping. A: The FU of VHH-R9 (blue and green) superimposed with VHH-RR1-52 (red). The CDRs are iden-
ti¢ed. For VHH-R9, the gap in CDR1 is localized by two black dots; CDR3 is replaced by the swapped segments, and L-strand 1 is shorter
and displaced outwards. The rest of the molecule superimposes well with VHH-RR1-52. B: Rainbow ribbon representation of a camelid VHH
displaying the closure mechanism. The L-strands are labelled 1^9, and the CDRs are identi¢ed. The interactions between the strands involved
in domain closing are symbolized by thick gray lines. Views made with PyMol [38].
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weakens strand 1b which assumes a more open position in
VHH-R9 and does not interact correctly with 9b. At that
stage, the strain induced by CDR3 might provoke the opening
of strand 9. Once this strain is released, conditions are re-
stored for establishing favorable connections between the do-
main-swapped strand 9 and another open VHH-R9. The as-
sociation then remains stable, since the strain exerted by the
short CDR3 is no longer present.
3.4. Formation of larger L-stranded structures
Besides the dimer association, the dimers establish a large
network of interactions in the crystal. It is formed of trigonal
structures involving the N- and C-terminal segments arranged
around the cubic threefold axis (Fig. 4A). Noteworthy, these
contacts could not be established if the N-terminus was left
intact. This ternary motif involves six VHH molecules linked
by a dense and large network of inter-strand hydrogen bonds
(Fig. 4A). This motif is rami¢ed in other identical motifs,
rotated by 90‡. They all form a continuous L-stranded struc-
ture spanning in three dimensions along the whole crystal
assembly (Fig. 4B).
4. Discussion
Crystals of immunoglobulin domains have been described
as a potential source of pathologies due to abnormal physio-
logical behavior. As an example, accumulation of non-cova-
lent immunoglobulin U light chain dimers (Bence^Jones pro-
tein) leads to renal complications, such as the Fanconi
syndrome, a speci¢c proximal tubule impairment [29]. In
this case as in other cases, however, accumulation of non-
swapped VL^VL dimers is observed, leading to micro-crystals
in the renal tubules. The only case of domain swapping re-
ported in immunoglobulins is the exchange of the VL and VH
domains in Fvs, a process used in biotechnology to provide
multiple speci¢cities to dimeric (or multimeric) Fvs [30]. Once
again, the immunoglobulin domains themselves (VL and VH)
have been shown to be intact in a natively folded state.
It has been reported that residues at the N-terminus of VH
domains are conformationally important, as illustrated in an
anti-ampicillin Fv domain [25,31]. Mutations introduced at
positions 6 and 10 induced a drastic conformational change
of the ¢rst nine residues, which were no longer in contact with
the core of the VH, but established a serendipitous contact
with a symmetry-related molecule. In VHH-R9, however, the
¢rst strand sequence, up to residue 15, is identical to those of
other VHHs (Fig. 1). The cleavage at positions 5^7 should
therefore be due to a proteolytic process occurring during
the long time of crystallization.
Dimerization by domain swapping has been reported to
have a high activation energy (slow kinetics) because of dras-
tic conformational changes, associated with a small thermo-
dynamic driving force, due to the similarity between the initial
and ¢nal structures [15,32]. Since no direct interface is ob-
served between the VHH FUs in the dimer and since the
VHH fold is conserved, the CDR3 strain release and the in-
teractions in the hinge extension should account for most of
the favorable energy changes. The length of the hinge has
been shown to play a crucial role in the case of the domain-
swapped bovine odorant binding protein (bOBP). Compared
to other OBPs, bOBP is devoid of disul¢de bridges and pos-
sesses a shorter turn, lacking a Gly residue, between its L-bar-
rel and its last K-helix [26]. As a consequence, helices are
exchanged between two molecules resulting in a C-terminal
domain-swapped dimer. By inserting a Gly residue after posi-
tion 121, a monomeric bOBP could be obtained [27], hence
con¢rming the essentiality of the hinge in the phenomenon.
Although not tested in the case of VHH-R9, we postulate that
the hinge size (the CDR3) is pivotal to yield domain swapping
in this case also.
Another favorable energy source might be the energy of
dimer association in the crystal. The strong hydrogen bonds
established between strands in dimers and between dimers
should account for a large proportion of the energy gained
upon swapping. The high concentration conditions used in
crystallization should displace the equilibrium towards the
dimer and, further, towards larger polymers possibly pre-
formed along the crystallization route. Lastly, the formation
of crystals should also displace the equilibrium to the dimers
by removing them from the soluble phase (mass action law).
Extended networks of interactions are observed in amyloid
¢bers, which are also the result of an initial domain-swapping
step [15,32^36]. Human cystatin C, a protein which reveals
amyloidic properties through a L68Q mutation, exists as a
Fig. 4. Representation of the crystal packing of VHH-R9. A: View of the peptide backbone along the threefold axis; the N- and C-termini are
identi¢ed and the main chain hydrogen bonds are displayed. B: View of the cubic crystal packing (I4132) parallel to a plane. A unit cell is dis-
played as a white square. For clarity, only residues in segment 90^113 have been displayed schematically as a broken line. Views made with
Turbo-Frodo [21].
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monomer or a domain-swapped dimer. Two monomers ex-
change two of their L-strands (plus an K-helix) creating a
long anti-parallel double-stranded free interface [35], resulting
in the same dumb-bell topology as VHH-R9. This dimer,
however, unlike VHH-RR9, exhibits classical crystal packing
contacts, based on van der Waals contacts and few hydrogen
bonds.
5. Conclusion
The crystal structure of VHH-R9 exhibits a domain-swap-
ping pattern unique in the immunoglobulin ¢eld, to date. The
crystal packing contacts are established through an extended
3D network of main chain strand^strand associations between
di¡erent dimers. Since VHH-R9 has been shown to be func-
tional in solution, having a low Kd against the hapten, it is
likely that during the time of the crystallization process (4^5
weeks) elements such as N-terminal cleavage, high concentra-
tion conditions and short CDR3, lead to the domain-swap-
ping and condensation phenomena.
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